Company
Headquarters: Chandigarh, India
₹340.4 Million
INR as of Aug. 1, 2021
US$4.6 Million
| Company | Market Cap (USD) |
|---|---|
| Zoetis Inc. | $89.09 B |
| MERCK Kommanditgesellschaft auf Aktien | $67.64 B |
| Takeda Pharmaceutical Company Limited | $47.71 B |
| Haleon plc | $38.90 B |
| PPD, Inc. | $16.58 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $586.39 B |
| UnitedHealth Group | $504.47 B |
| Novo Nordisk | $461.52 B |
| Johnson & Johnson | $387.50 B |
| Merck | $296.51 B |
Parabolic Drugs Limited develops, manufactures, and sells active pharmaceutical ingredients (API) and API intermediates in India. The company offers oral and sterile semi synthetic penicillin APIs; oral and sterile cephalosporin APIs in antibiotic area; non-antibiotic APIs for cardiovascular, NSAID, anti-hypertensive, and osteoporosis therapeutic areas; and calcium sennoside, colchicine, raubasine, reserpine, thiocolchicoside, vinpocetine, and yohimbine. It also provides custom research and manufacturing services to pharma companies, including research and development, and manufacturing services for NCE and generics; IPR support for process design and infringement guidance; and QA, QC, and regulatory support for meeting quality and documentation requirements. The company also exports its products to approximately 51 countries. Parabolic Drugs Limited was founded in 1996 and is based in Chandigarh, India.
Top 1-year algo backtest: +284.14%
$10,000 in April 2023 would now be $38,414 by following this algorithm daily at market close.
Boost your stocks returns with Disfold AI... Now!
Try Disfold AI for FREE
Parabolic Drugs Ltd has the following listings and related stock indices.
Stock: NSE: PARABDRUGS wb_incandescent